{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:19:38Z","timestamp":1785194378673,"version":"3.55.0"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108673"],"award-info":[{"award-number":["JP24fk0108673"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24gm1610013"],"award-info":[{"award-number":["JP24gm1610013"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24jm0210111"],"award-info":[{"award-number":["JP24jm0210111"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,1,5]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although the incidence of amikacin (AMK)-resistant <jats:italic>Mycobacterium avium<\/jats:italic> complex (MAC) pulmonary disease (PD) is suspected to have increased, limited data are available on AMK-resistant MAC-PD. This study evaluated the risk factors associated with AMK resistance, the molecular characteristics of the AMK-resistant isolates, and treatment outcomes of patients with AMK-resistant MAC-PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective case\u2013control study included 73 patients with severe and refractory MAC-PD who had a history of aminoglycoside drug use. Patients with initial and repeat AMK minimum inhibitory concentration (MIC) \u226564\u2005\u03bcg\u00b7mL<jats:sup>\u22121<\/jats:sup> were classified as AMK-resistant. To clarify the clinical outcomes and prognosis, an observational study was conducted. 21 patients with AMK resistance (AMK-resistant) and 52 controls (AMK-susceptible) were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In all cases of AMK resistance where previous isolates were available, the AMK MICs were elevated compared to the levels prior to aminoglycoside administration. In the multivariate analysis of risk factors, clarithromycin resistance (OR 6.31, 95% CI 1.68\u201323.7) and &gt;12\u2005months of total duration of aminoglycoside use (OR 4.69, 95% CI 1.09\u201320.2) were identified as independent risk factors for AMK resistance. 12 (57%) out of 21 AMK-resistant isolates were found to have mutations in the <jats:italic>rrs<\/jats:italic> region. There was a significant difference between the AMK-resistant and AMK-susceptible groups in terms of worsening outcomes, including the introduction of home oxygen therapy (38% <jats:italic>versus<\/jats:italic> 12%; p=0.01) and 3-year mortality (33% <jats:italic>versus<\/jats:italic> 10%; p=0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Better management strategies for patients with severe and refractory MAC-PD are crucial. This includes placing a strong emphasis on preventing AMK resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1183\/23120541.01084-2024","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T13:10:37Z","timestamp":1738847437000},"page":"01084-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors, molecular analysis and treatment outcomes of amikacin-resistant <i>Mycobacterium avium<\/i> complex pulmonary disease"],"prefix":"10.1183","volume":"11","author":[{"given":"Tatsuya","family":"Kodama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Aono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-1604","authenticated-orcid":false,"given":"Keiji","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Furuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-6995","authenticated-orcid":false,"given":"Masashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuyo","family":"Chikamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-077X","authenticated-orcid":false,"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-9275","authenticated-orcid":false,"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025081102301270000_11.4.01084-2024.1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2019.05.001","article-title":"Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan","volume":"152","author":"Furuuchi","year":"2019","journal-title":"Respir Med"},{"key":"2025081102301270000_11.4.01084-2024.2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2206.151086"},{"key":"2025081102301270000_11.4.01084-2024.3","first-page":"341","article-title":"Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan","volume":"16","author":"Izumi","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025081102301270000_11.4.01084-2024.4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jiac.2015.01.004","article-title":"Increasing patients with pulmonary Mycobacterium avium complex disease and associated underlying diseases in Japan","volume":"21","author":"Ito","year":"2015","journal-title":"J Infect Chemother"},{"key":"2025081102301270000_11.4.01084-2024.5","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201607-573OC"},{"key":"2025081102301270000_11.4.01084-2024.6","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01612-13"},{"key":"2025081102301270000_11.4.01084-2024.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350603"},{"key":"2025081102301270000_11.4.01084-2024.8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2025081102301270000_11.4.01084-2024.9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"7","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025081102301270000_11.4.01084-2024.10","unstructured":"Clinical Laboratory Standards Institute (CLSI) . Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp, and Other Aerobic Actinomycetes. 2nd Edn. CLSI supplement M24S. Berwyn, Clinical Laboratory Standards Institute, 2023."},{"key":"2025081102301270000_11.4.01084-2024.11","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201604-246OC"},{"key":"2025081102301270000_11.4.01084-2024.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-450OC"},{"key":"2025081102301270000_11.4.01084-2024.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01240-16"},{"key":"2025081102301270000_11.4.01084-2024.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01027-15"},{"key":"2025081102301270000_11.4.01084-2024.15","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium complex and Mycobacterium abscessus clinical isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2025081102301270000_11.4.01084-2024.16","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00516-19"},{"key":"2025081102301270000_11.4.01084-2024.17","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1093\/jac\/dkad317","article-title":"In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022","volume":"78","author":"Calado Nogueira de Moura","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025081102301270000_11.4.01084-2024.18","doi-asserted-by":"crossref","first-page":"e0162622","DOI":"10.1128\/jcm.01626-22","article-title":"MGIT-seq for the identification of nontuberculous mycobateria and drug resistance: a prospective study","volume":"61","author":"Fukushima","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2025081102301270000_11.4.01084-2024.19","doi-asserted-by":"crossref","first-page":"e0008424","DOI":"10.1128\/aac.00084-24","article-title":"Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease","volume":"68","author":"Minuk","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025081102301270000_11.4.01084-2024.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"2025081102301270000_11.4.01084-2024.21","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1016\/j.tube.2023.102427","article-title":"Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex","volume":"143","author":"Park","year":"2023","journal-title":"Tuberculosis"},{"key":"2025081102301270000_11.4.01084-2024.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00170-2018"},{"key":"2025081102301270000_11.4.01084-2024.23","unstructured":"The Japanese Respiratory Society\/The Japan Society for Respiratory Care and Rehabilitation . Oxygen Therapy Manual. Revised version. Japan, The Japan Society for Respiratory Care and Rehabilitation, 2017."},{"key":"2025081102301270000_11.4.01084-2024.24","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9897"},{"key":"2025081102301270000_11.4.01084-2024.25","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot3972"},{"key":"2025081102301270000_11.4.01084-2024.26","unstructured":"Andrews S . A quality control tool for high throughput sequence data. Fast QC; 2010. Date last accessed: 10 February 2024. www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/"},{"key":"2025081102301270000_11.4.01084-2024.27","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2025081102301270000_11.4.01084-2024.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01505-12"},{"key":"2025081102301270000_11.4.01084-2024.29","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00466-2021"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01084-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:30:23Z","timestamp":1754904623000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01084-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,11]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1183\/23120541.01084-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01084-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}